METAL CONJUGATED MONOCLONAL ANTIBODIES FOR TUMOR DIAGNOSIS AND THERAPY

肿瘤相关单克隆抗体是潜在的治疗剂， 恶性细胞的细胞毒性剂的选择性载体。 我们正在测试 这种假说在几种动物模型系统中得到证实：一种是肿瘤病毒， 另一种是裸鼠体内的人肿瘤异种移植。 使用的各种杀细胞剂是放射性同位素。 他们的 当与抗体缀合时的相对治疗功效是 测定并比较单独的单克隆抗体。 同位素 包括高度杀肿瘤的α发射亲本 放射性同位素Pb-212或Bi-212。 不同螯合物的合成， 正在设计实现这些目标所需的放射化学分离方法 并减少到临床实践。 同位素治疗的结果 与通过使用抗体缀合的毒素或药物获得的那些相比 关于肿瘤生长、消退或治愈。 这些研究将为人类医学提供设计或 通过选择性靶向杀细胞剂合理治疗恶性肿瘤 肿瘤和转移瘤。 用于该项目的新螯合物已经合成，并在 测试，并且迄今为止已经证明对于细胞的放射生物学研究是有用的。 用α粒子标记的抗体杀死。

Tumor-associated monoclonal antibodies are potential therapeutic agents as selective carriers of cytotoxic agents to malignant cells. We are testing this hypothesis in serveral animal model systems: one is a tumor virus leukemia of mice, another is human tumor xenographs in nude athymic mice. The various cytocidal agents being employed are radioisotopes. Their relative therapeutic efficacy when conjugated to antibodies is being assayed and compared that of monoclonal antibodies alone. The isotopes to be employed include the highly tumoricidal alpha emitting parent radioisotopes Pb-212 or Bi-212. The syntheses of different chelates and radiochemical separations required for these objectives are being devised and reduced to clinical practice. Results from isotopic therapy are being compared with those obtained by use of antibody conjugated toxins or drugs with respect to tumor growth, regression or cure. These studies will provide for human medicine a basis for design or rational therapy of malignancies by selectively targeting cytocidal agents to tumors as well as metastases. New chelates for use in this project have been synthesized and are in testing, and have thus far proven useful for Radiobiology studies of cell killing with alpha particle labeled antibody.